Company Overview of Diartis Pharmaceuticals, Inc.
Diartis Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic proteins for the treatment of metabolic disorders. Its development portfolio includes VRS-859, a glucagon-like peptide-1 analog that provides improved therapeutic outcomes for Type 2 diabetic patients. The company was incorporated in 2010 and is based in Redwood City, California.
275 Shoreline Drive
Redwood City, CA 94065
Founded in 2010
Key Executives for Diartis Pharmaceuticals, Inc.
Senior Vice President of Business Development
Compensation as of Fiscal Year 2014.
Diartis Pharmaceuticals, Inc. Key Developments
Diartis Pharmaceuticals, Inc. Presents VRS-859 Positive Clinical Results for Type 2 Diabetes
Oct 2 12
Diartis Pharmaceuticals, Inc. is presenting positive data from its completed Phase 1 multicenter clinical trial of VRS-859 (exenatide-XTEN) at the European Association for the Study of Diabetes (EASD) 48th Annual Meeting which began on October 1 in Berlin-Charlottenburg. VRS-859, a long-acting glucagon-like peptide-1 (GLP-1) analog, is being developed as a once monthly treatment for patients with type 2 diabetes mellitus (T2DM). The Phase 1 multicenter, blinded, placebo-controlled, single-ascending dose study was designed to evaluate the safety and tolerability of VRS-859 as well as the ability to maintain glycemic control for one month in T2DM patients after a single dose. The Phase 1 results in T2DM patients demonstrate that all doses administered (up to 200 mg) were well tolerated and no unexpected adverse events were noted. Furthermore, the PK of VRS-859 in these patients was dose linear and comparable to the profile predicted from preclinical studies, validating the half-life extension capability of the XTEN technology and supporting a once monthly dosing regimen for VRS-859. These results support the company's plan to conduct a 6-month repeat dose study to determine a safe and efficacious subcutaneous dose of VRS-859 in patients with T2DM. About VRS-859 The compound has been designed to provide improved therapeutic outcomes for T2DM patients including robust and sustained improvements in HbA1c, improved tolerability, prolonged half-life (up to monthly dosing), as well as enhanced administration of a liquid formulation via a fine-gauge needle. It is hoped that upon successful development, VRS-859 may allow T2DM patients to safely manage their glucose with a therapy that is superior to current treatments for diabetes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries